Arcturus Therapeutics Holdings, Inc.

Arcturus Therapeutics Holdings Inc. is a biotechnology company specializing in the development and commercialization of innovative therapeutics based on its novel nucleic acid technologies. The primary focus of the company is on designing RNA medicines that offer treatment possibilities for rare diseases and infectious diseases, expanding the potential for targeted, efficient solutions in areas with unmet clinical needs. Arcturus Therapeutics is known for its proprietary platform, LUNAR®, which harnesses lipid-mediated delivery systems to enhance the stability and biodistribution of RNA therapeutics. The company actively engages in collaborations with global pharmaceutical firms to accelerate the development of its therapeutic candidates and leverage complementary technological expertise. Operating within the highly dynamic and impactful biotechnology sector, Arcturus plays a key role in advancing RNA-based solutions and contributes to innovation that could transform traditional therapeutic approaches. As such, it holds significance in the market as part of the ongoing evolution in biopharmaceutical research and development, particularly in the realm of precision medicine.